Thrombotic thrombocytopenic purpura (TTP) has a devastating prognosis without adapted management. Sources of misdiagnosis need to be identified to avoid delayed treatment. We studied 84 patients with a final diagnosis of severe (<10%) acquired ADAMTS13 deficiency-associated TTP from our National database that included 423 patients, who had an initial misdiagnosis (20% of all TTP). Main diagnostic errors were attributed to autoimmune thrombocytopenia, associated (51%) or not (37%) with autoimmune hemolytic anemia. At admission, misdiagnosed patients were more frequently females (P 5 .034) with a history of autoimmune disorder (P 5 .017) and had organ involvement in 67% of cases; they had more frequently antinuclear antibodies (P 5 .035), a low/undetectable schistocyte count (P 5 .001), a less profound anemia (P 5 .008), and a positive direct antiglobulin test (DAT) (P 5 .008). In multivariate analysis, female gender (P 5 .022), hemoglobin level (P 5 .028), a positive DAT (P 5 .004), and a low schistocytes count on diagnosis (P < .001) were retained as risk factors of misdiagnosis. Platelet count recovery was significantly 
longer in the misdiagnosed group (P 5 .041) without consequence on mortality, exacerbation and relapse. However, patients in the misdiagnosed group had a less severe disease than those in the accurately diagnosed group, as evidenced by less organ involvement at TTP diagnosis (P 5 .006) .
TTP is frequently misdiagnosed with autoimmune cytopenias. A low schistocyte count and a positive DAT should not systematically rule out TTP, especially when associated with organ failure.
| I N T R O D U C T I O N
Thrombotic thrombocytopenic purpura (TTP) is a specific form of thrombotic microangiopathy (TMA) characterized by profound cytopenia (thrombocytopenia and hemolytic anemia) and widespread microvascular thrombi responsible for multiorgan failure of variable severity with an overall mortality rate of 20%. [1] [2] [3] [4] [5] This disease is related to a severe deficiency of the von Willebrand factor-cleaving protease ADAMTS13 (A Disintegrin And Metalloproteinase with ThromboSpondin-1 motifs, 13th member) leading to the accumulation of ultra large multimers of von Willebrand factor (ULVWF) in plasma. Currently, the identification of a severe ADAMTS13 deficiency is considered as part of the positive diagnosis. 6 TTP is a devastating disease that requires a rapid diagnosis and an adapted management in emergency. However, the diagnosis of TTP in an emergency setting may be challenging given its rarity (<4 cases/10 6 population/year). 7 Moreover, as TTP is characterized by peripheral cytopenias, it may be confounded with more common conditions, particularly autoimmune cytopenias (AIC) such as autoimmune thrombocytopenia associated or not with autoimmune hemolytic anemia (Evans syndrome), which represents an additional challenge in the positive diagnosis. 8 In this context, the assessment of ADAMTS13 activity is of particular help to ascertain the diagnosis of TTP in patients with peripheral cytopenias. 9 However, a rapid ADAMTS13 activity assessment is not available in all centers routinely, leading to diagnostic wanderings with potentially severe consequences on prognosis by delaying therapeutic plasma exchange (TPE) in cases of diagnosis uncertainty.
Therefore, it is crucial to identify accurately the reasons leading to misdiagnose TTP with AIC and the consequences on prognosis.
| M E T H O D S

| Patients and treatment
We retrospectively reviewed admission data of all patients of the when another diagnosis than TTP was first retained on admission and "accurately diagnosed group" when TTP was immediately retained. We reviewed the presence of a positive DAT and schistocytes. A low schistocyte count was defined by schistocytes inferior to one by field on a blood smear or 1% of red blood cells on automated measurement.
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Only blood smears with a quantitative value were considered.
Autoimmune disorder (AID) associated at admission and treatments used before the final diagnosis of TTP were also reported.
In addition, for each patient, the occurrence of a relapse and an exacerbation were systematically registered. Definitions of patients' outcomes (complete remission, durable remission, exacerbation, relapse, refractoriness and suboptimal response) are detailed in Supporting Information Table 1 . 
| Evaluation of ADAMTS13 activity and anti-ADAMTS13 antibodies
Blood collection, plasma preparation, and ADAMTS13 activity measurement were performed as previously described. 1 Severe ADAMTS13
deficiency was defined as ADAMTS13 activity <10%, moderate Patients with no detectable anti-ADAMTS13 antibodies on diagnosis but who recovered partially or completely ADAMTS13 activity at time of clinical remission were also considered as having an acquired TTP.
| Statistical methods
Median with interquartile range ([IQR] 25-75%) and percentage (%)
were respectively determined for continuous and categorical variables.
Differences between groups were assessed by the chi-square test or
Fisher's exact test for categorical variables and by the Mann-Whitney U test for continuous variables. Variables strongly associated with diagnostic error at P < 0.05 were then included in a backward multivariable analysis. According to our size of cohort, only six variables were tested, to decrease misinterpretation. To compare time to platelet count recovery, with the corresponding 95% confidence interval (95%CI), in the misdiagnosed patients and in the accurately diagnosed patients, we used the Kaplan-Meier estimator. Curves for platelet count recovery were compared between groups using the Log-rank test. Two-sided P < .05 was considered statistically significant.
| R E S U LTS
| Study group
From May 2000 to May 2014, among 2927 patients with a diagnosis of TMA included in the national registry, 423 had an acquired TTP. Of these, 84 (20%) were misdiagnosed, which included 74 (17.5%) patients initially misdiagnosed as having an AIC (Supporting Information Figure 1 ).
| Diagnostic errors
Patients were mainly misdiagnosed as having Evans syndrome (51% of cases) and autoimmune thrombocytopenia (37% of cases). Other miscellaneous diagnostic errors were allocated to a diagnosis of heparin induced thrombocytopenia, HELLP syndrome, lymphoma, drug toxicity (two cases each), myelodysplastic syndrome, and catastrophic antiphospholipid syndrome (one case each). None of these patients received TPE or plasma infusion as initial treatment. Intravenous immunoglobulins were infused in 29 (34%) patients. Forty-five patients (54%) received steroids alone. Rituximab, splenectomy and danazol (one case each) were also used before TTP diagnosis. In most cases, the former diagnosis was revised (and TTP diagnosis was finally considered) because initial treatment provided no efficacy (49%) and/or because organ failure occurred (34%).
| Comparison of clinical features between groups at admission
Time from admission to TTP diagnosis was significantly longer in the misdiagnosed group than in the accurately diagnosed group ( Table 1) .
By multivariate analysis, female gender (P 5 .022), hemoglobin level (P 5 .028), a positive DAT (P 5 .004), and a low or undetectable schistocytes count on diagnosis (P < .001) were retained as significant risk factors associated with a former misdiagnosis of AIC in patients with TTP (Table 2) . 
| Treatment and outcome
Steroids were more frequently given in the misdiagnosed group (P 5 .002). Similarly, patients from this group received more platelet transfusions (P 5 .021). Of note, steroids and/or intravenous immunoglobulins alone did not improve cytopenias, irrespective of DAT status.
Time to platelet count recovery was significantly longer in the misdiagnosed group (log-rank test: P 5 .04) (Figure 1 ). Unexpectedly, among non-survivors, time from admission to death was longer in misdiagnosed patients than in patients with a correct diagnosis (13 [IQR, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) days vs. 6 [IQR, 2-9] days, respectively; P 5 .023), and salvage therapies (i.e., rituximab, vincristine, or cyclophosphamide) were performed more frequently (80% vs. 35%, respectively, P 5 .009). Death rate, exacerbations and relapse were comparable between groups (Table 3) . Median follow-up was 33 [IQR, months and comparable between groups (not shown).
| Comparison of practices
The percentage of misdiagnosed patients was significantly higher dur- 
| DISCUSSION
TTP is a spontaneously fatal disease which prognosis was outstandingly improved with intensive, TPE-based treatment. [2] [3] [4] Therefore, a rapid diagnosis represents a major goal and sources of misdiagnosis need to be identified to avoid diagnostic wandering and delayed adapted treatment that may translate in increased morbidity and mortality. In this national study, we report an unexpectedly high number (20%) of TTP patients initially misdiagnosed with an AIC, which translated in a 5-day delay in the adequate management with a longer time to platelet count recovery and more salvage therapies although overall mortality remained comparable between the two groups. Importantly however, misdiagnosed patients represent de facto selected patients who survived to the consequences of misdiagnosis, and we cannot exclude that some patients with a misdiagnosis of AIC may have died before TTP was diagnosed (and therefore not reported in our registry), which could have underestimated death rate and the severity of misdiagnosed patients.
The misdiagnosis of TTP with AIC has several reasons. The higher prevalence of AIC, which are three to eightfold higher than that of TTP, 14 and the relatively recent availability of ADAMTS13 as a reliable tool to distinguish TTP from other diseases, certainly account for such diagnostic errors. Moreover, to identify a microangiopathic hemolytic anemia may be challenging, particularly in the emergency setting;
indeed, we could observe among our large series of patients that schistocytes may be low or absent in more than one third of cases at first presentation, and be positive in the following days. An additional challenge in the diagnosis of microangiopathic hemolytic anemia is the possibility to observe a positive, low titer DAT that rather suggests the diagnosis of autoimmune hemolytic anemia, in 10% of all patients.
Whereas positive DAT was observed anecdotally in the accurately diagnosed group (<5% of cases), which is in accordance with previous reports from other groups, 2 almost 20% of patients in the misdiagnosed group had a positive DAT. However, further studies should now assess more in detail the properties of antibodies directed against erythrocytes in these patients, and particularly their specificity through elution, to better understand their possible pathophysiological relevance. This unexpected result could be at least in part explained by an increased awareness in the diagnosis of TTP, allowing diagnosing cases of TTP formerly undiagnosed before the era of ADAMTS13 availability.
These two confounding features therefore define a subset of patients (with low/absent schistocytes and a positive DAT at first presentation;
10% of the total TTP population) with typical features of AIC and for whom TTP diagnosis is therefore particularly challenging. From these results, we propose that a positive DAT should not systematically rule out TTP diagnosis. In addition, the repeated search for schistocytes should be more systematically performed in patients with peripheral cytopenias, to minimize the risk of misdiagnosis, particularly in patients with organ failure in whom the diagnosis of TTP should be clearly preferred until ADAMTS13 activity is available. In line with this statement, we observed a strikingly high number of TTP patients formerly diagnosed with an AIC, despite organ involvement that should have rather suggested TTP. Indeed, almost half of misdiagnosed patients had a cerebral involvement, whereas on the opposite neurologic events in AIC are very uncommon (1-4% of cases) 15, 16 and mainly due to intracranial hemorrhage. In the present study importantly, the occurrence of cerebral manifestations after an initial diagnosis of AIC was the main reason of diagnosis revision that led to the final diagnosis of TTP.
Although we found that the number of misdiagnosed patients significantly decreased throughout time, suggesting that TTP is more frequently recognized than in the past, a still important number of misdiagnoses remain. These observations suggest that intensive awareness campaigns should be conducted for practitioners potentially involved in the diagnosis of TTP such as intensivists and urgentists, hematologists, internists and nephrologists, but also general practitioners. Awareness campaigns, aimed at improving diagnosis and early management of TTP, should be facilitated by National plans, in an order to better widespread knowledge on these rare conditions, 1, 15 and offer practitioners a recourse activity. 
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